Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preferential HLA usage in the influenza virus-specific CTL response.

Adrianus C M Boon1, Gerrie De Mutsert, Ron A M Fouchier

  • 1Department of Virology and World Health Organization National Influenza Center, Erasmus Medical Center, Rotterdam, The Netherlands.

Journal of Immunology (Baltimore, Md. : 1950)
|March 23, 2004
PubMed
Summary

Human leukocyte antigen (HLA) class I alleles show preferential use in influenza virus-specific T cell responses. Specific HLA-A and HLA-B alleles are key in mounting cytotoxic T lymphocyte (CTL) immunity against different influenza viruses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice.

NPJ vaccines·2026
Same author

Antigenic characterization of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal models.

bioRxiv : the preprint server for biology·2026
Same author

Characterization of aerosols generated during suspected aerosol-generating procedures in healthcare settings.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Identification of immunodominant T cell epitopes in SARS-CoV-2 spike protein in Syrian hamsters.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals.

Cell reports. Medicine·2026
Same author

Inhibitors of membrane associated serine proteases block replication of coronavirus SARS-CoV-2 and influenza virus H1N1.

European journal of medicinal chemistry·2025

Area of Science:

  • Immunology
  • Virology
  • Genetics

Background:

  • Cytotoxic T lymphocyte (CTL) responses are crucial for controlling viral infections.
  • Human Leukocyte Antigen (HLA) class I molecules present viral peptides to CD8+ T cells, initiating CTL responses.
  • The specific contribution of individual HLA alleles to antiviral immunity is not fully understood.

Purpose of the Study:

  • To investigate the preferential or equal usage of individual HLA class I alleles (HLA-A and HLA-B) in human influenza virus-specific CTL responses.
  • To determine how specific HLA alleles influence the magnitude and restriction of CTL responses to influenza A and B viruses.

Main Methods:

  • Obtained peripheral blood mononuclear cells (PBMC) from HLA-A and -B identical donors.
  • Stimulated PBMC with influenza virus and assessed virus-specific CD8+ T cell populations.

Related Experiment Videos

  • Quantified IFN-gamma and TNF-alpha producing cells using restimulation with C1R cells expressing single HLA-A or -B alleles.

    • Main Results:

    • HLA-B*2705 and HLA-B*3501 were preferentially used in influenza A virus-specific CTL responses.
    • HLA-B*0801 and HLA-A*0101 showed minor contributions in the presence of HLA-B*2705.
    • CTL responses to influenza B virus were primarily directed toward HLA-B*0801-restricted epitopes.
    • Preferential HLA allele usage varied depending on the specific influenza virus (A vs. B).

    Conclusions:

    • Individual HLA class I alleles are not equally utilized in antiviral CTL responses.
    • The preferential use of HLA alleles is virus-dependent, highlighting allele-specific roles in immunity.
    • Understanding HLA allele preferences is critical for predicting and potentially manipulating antiviral immunity.